UTHR - United Therapeutics - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US91307C1027

Chronic disease treatments, Pulmonary hypertension medicines, Cancer therapies

United Therapeutics Corporation is a biotechnology company that focuses on developing and commercializing innovative products to address the unmet medical needs of patients suffering from chronic and life-threatening diseases worldwide.

The company's product portfolio includes Tyvaso DPI, a groundbreaking inhaled dry powder medication delivered via pre-filled and single-use cartridges, as well as Tyvaso, an inhaled solution administered through an ultrasonic nebulizer. Both products are designed to improve exercise capacity and alleviate symptoms associated with pulmonary arterial hypertension (PAH).

In addition to its PAH treatments, United Therapeutics offers Orenitram, a tablet dosage form of treprostinil that helps delay disease progression and enhance exercise capacity in PAH patients. The company also markets Adcirca, an oral PDE-5 inhibitor that enhances exercise ability in PAH patients.

Furthermore, United Therapeutics commercializes Unituxin (dinutuximab) injection, a monoclonal antibody used to treat high-risk neuroblastoma. The company also sells the Remunity Pump, a system consisting of a pump and separate controller designed for Remodulin, a treatment for PAH.

United Therapeutics has a robust pipeline of products in development, including RemoPro and Ralinepag for the treatment of PAH, Aurora-GT, a gene therapy product aimed at rebuilding blood vessels in the lungs, and Nebulized Tyvaso, a potential treatment for idiopathic pulmonary fibrosis. The company is also exploring the development of xenografts, which are development-stage organ products.

The company has established strategic partnerships with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil, with MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device, and with Arena Pharmaceuticals, Inc. to develop Ralinepag.

Founded in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland, and is committed to improving the lives of patients worldwide. For more information, please visit their website at https://www.unither.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for UTHR - United Therapeutics  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for UTHR - United Therapeutics  - Stock Price & Dividends

UTHR Stock Overview

Market Cap in USD 14,133m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1999-06-17

UTHR Stock Ratings

Growth 5y 83.0
Fundamental 77.0
Dividend -
Rel. Performance vs Sector 3.01
Analysts 4.19/5
Fair Price Momentum 366.77 USD
Fair Price DCF 447.08 USD

UTHR Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

UTHR Growth Ratios

Growth 12m 34.51%
Growth Correlation 12m 35%
Growth Correlation 3m 86%
CAGR 5y 34.37%
CAGR/Mean DD 5y 3.48
Sharpe Ratio 12m 1.18
Alpha vs SP500 12m 17.84
Beta vs SP500 5y weekly 0.61
ValueRay RSI 79.56
Volatility GJR Garch 1y 25.36%
Price / SMA 50 12.04%
Price / SMA 200 33.74%
Current Volume 510.1k
Average Volume 20d 596.4k

External Links for UTHR Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of UTHR stocks?
As of July 19, 2024, the stock is trading at USD 328.67 with a total of 510,114 shares traded.
Over the past week, the price has changed by +1.48%, over one month by +7.39%, over three months by +38.72% and over the past year by +32.40%.
What are the forecast for UTHR stock price target?
According to ValueRays Forecast Model, UTHR United Therapeutics will be worth about 403.7 in July 2025. The stock is currently trading at 328.67. This means that the stock has a potential upside of +22.84%.
Issuer Forecast Upside
Wallstreet Target Price 306.1 -6.87
Analysts Target Price 284.6 -13.4
ValueRay Target Price 403.7 22.8